April 4, 2024
Docket Number: FDA-2023-D-4719 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This FDA guidance provides information to sponsors and nonclinical laboratories regarding the […]
April 4, 2024
Paxlovid does not significantly alleviate symptoms of COVID-19 compared with placebo among nonhospitalized adults, a new study published on April 3 in The New England Journal […]
April 4, 2024
Enrolment in a trial investigating a novel gene editing therapy in patients with heterozygous familial hypercholesterolemia (HeFH) has been paused after laboratory abnormalities, including a grade […]
April 4, 2024
Docket Number: FDA-2019-D-1264 Issued by: Guidance Issuing Office Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Over the past few decades, FDA […]
April 4, 2024
Amylyx Pharmaceuticals has announced plans to take sodium phenylbutyrate–taurursodiol (Relyvrio and Albrioza), its drugs for amyotrophic lateral sclerosis (ALS), off the market in the United States […]
April 4, 2024
TOPLINE: Nearly four in every 1000 youths and five in every 1000 adults in the United States reported having type 1 diabetes (T1D) in the National […]
April 4, 2024
Dogs can detect stress-related compounds in the breath of people experiencing early signs of trauma, including those with posttraumatic stress disorder (PTSD), a new proof-of-concept study […]
April 4, 2024
Last year, oncologists dealt with the most severe cancer drug shortage to date. Over about 6 months in 2023, cancer centers across the United States struggled […]
April 4, 2024
PARIS — On Thursday, March 21, French lawmakers reached an agreement on a bill that proposes the prohibition of disposable e-cigarettes by the end of 2024. […]